



UK Health  
Security  
Agency

# National influenza and COVID-19 surveillance report

Week 37 report (up to week 36 2024 data)

12 September 2024

# Contents

Executive summary .....	3
Overall .....	3
Influenza .....	3
COVID-19 .....	3
Other viruses .....	3
Laboratory surveillance .....	4
Respiratory DataMart system (England) .....	4
Primary care surveillance .....	6
RCGP sentinel swabbing scheme in England .....	6
Secondary care surveillance .....	8
COVID-19, SARI Watch .....	8
ECMO, SARI Watch .....	10
International update .....	11
Global COVID-19 update .....	11
Global influenza update .....	11
Influenza in Europe .....	11
Influenza in North and South America .....	11
Influenza in Australia .....	11
Other respiratory viruses .....	11
Additional surveillance sources .....	12
COVID-19 deaths .....	12
All-cause mortality assessment (England) .....	12
Flu Detector .....	12
Syndromic surveillance .....	12
Related links .....	13
About the UK Health Security Agency .....	14

For additional information including regional data on COVID-19 and other respiratory viruses, and other data supplementary to this report, please refer to the [accompanying graph pack](#).

For additional information regarding data sources, please refer to [sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#).

## Executive summary

This report summarises the information from the surveillance systems which are used to monitor COVID-19 (caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)), influenza, and diseases caused by seasonal respiratory viruses in England. This report is based on data from week 36 of 2024 (between 2 and 8 September 2024).

## Overall

In week 36, influenza circulated at low levels and COVID-19 activity stabilised after a few weeks of decreases.

## Influenza

Through Respiratory DataMart, influenza positivity increased slightly to 1.1% in week 36 compared with 1.0% in the previous week.

## COVID-19

Through Respiratory DataMart, SARS-CoV-2 positivity remained stable at 7.6% compared with 7.6% in the previous week.

Overall, COVID-19 hospital admissions remained stable at 2.37 per 100,000 compared with 2.28 per 100,000 in the previous week. Hospitalisations were highest in those aged 85 years and over. COVID-19 intensive care unit (ICU) admissions remained low and decreased to 0.07 per 100,000 in week 36 compared with 0.11 per 100,000 in the previous week.

## Other viruses

Through Respiratory DataMart, respiratory syncytial virus (RSV) positivity remained low at 0.3%, with the highest positivity in those aged under 5 years at 1.9%. Adenovirus positivity remained stable at 1.8%, with the highest positivity in those aged under 5 years at 4.7%. Human metapneumovirus (hMPV) positivity decreased slightly to 0.7%, with the highest positivity in those aged between 45 and 64 years at 1.6%. Parainfluenza positivity remained stable at 1.3%, with the highest positivity in those aged under 5 years at 3.3%. Rhinovirus positivity decreased slightly to 6.1% overall, with the highest positivity in those aged under 5 years at 16.3%.

# Laboratory surveillance

## Respiratory DataMart system (England)

In week 36, data is based on reporting from 12 out of the 16 sentinel laboratories.

In week 36, 3,302 respiratory specimens reported through the Respiratory DataMart System were tested for influenza. There were 37 positive samples for influenza; 9 influenza A(not subtyped), 21 influenza A(H3N2), 3 influenza A(H1N1)pdm09, and 4 influenza B. Overall, influenza positivity remained stable at 1.1% in week 36 compared with 1.0% in the previous week.

In week 36, 3,022 respiratory specimens reported through the Respiratory DataMart System were tested for SARS-CoV-2. There were 239 positive samples for SARS-CoV-2 with an overall positivity of 7.6%, which remained stable in comparison with 7.6% in the previous week. The highest positivity was seen in adults aged over 65 years at 10.1%.

RSV positivity remained low at 0.3%, with the highest positivity in those aged under 5 years at 1.9%.

Adenovirus positivity decreased slightly to 1.8%, with the highest positivity in those aged under 5 years at 5%.


Human metapneumovirus (hMPV) positivity decreased slightly to 0.7%, with the highest positivity in those aged between 45 and 64 years at 1.6%.

Parainfluenza positivity decreased slightly to 1.3%, with the highest positivity in those aged under 5 years at 3.3%.


Rhinovirus positivity decreased slightly to 6.1% overall, with the highest positivity in those aged under 5 years at 16.3%.

DataMart data is provisional and subject to retrospective updates.

**Figure 1a. Respiratory DataMart weekly positivity (%) for influenza, SARS-CoV-2, RSV and rhinovirus, England**



**Figure 1b. Respiratory DataMart weekly positivity (%) for adenovirus, hMPV and parainfluenza, England**



## Primary care surveillance

### RCGP sentinel swabbing scheme in England

Based on the date that samples were taken, in week 35 of 2024 (week commencing 26 August 2024) 146 samples were received through the GP sentinel swabbing scheme in England. Due to a planned shutdown of the laboratory, only 16 of these had a known result ([Figure 2](#)).


There were no available results for week 36. The proportion of detections among all positive samples is not calculated when the number of samples with a result is fewer than 50. Therefore, no positivity is reported for both weeks 35 and 36.

In previous reports, [Figure 2](#) was produced based on the date samples were received in the reference laboratory. From 23 November 2023 (week 47 report) this figure has been updated to be based on the date samples were taken.

From 27 November 2023, swabbing was temporarily increased in the Yorkshire and Humber region in response to the [identification of a case of influenza A\(H1N2\)v](#). This may lead to an over-representation of the Yorkshire and Humber region.

More extensive data can be found on the [RCGP virology dashboard](#).

**Figure 2. Number of samples tested for SARS-CoV-2, influenza, and other respiratory viruses in England by week, GP sentinel swabbing [note 1]**



[note 1] Unknown category corresponds to samples with no result yet.

## Secondary care surveillance

### COVID-19, SARI Watch


Surveillance of COVID-19 hospitalisations to all levels of care and surveillance of admissions to ICU or high-dependency unit (HDU) for COVID-19 are both mandatory with data required from all acute NHS trusts in England. Please note that the SARI Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020.

In week 36 (ending 8 September 2024), the overall weekly hospital admission rate for COVID-19 remained stable at 2.37 per 100,000 compared with 2.28 per 100,000 in the previous week. By UKHSA region, the highest hospital admission rate for COVID-19 was observed in the North East (remaining stable at 3.96 per 100,000 from 3.76 per 100,000 in the previous week). Decreases or stabilisation occurred in most of the remaining regions. By age group, the highest hospital admission rate for confirmed COVID-19 continued to be in those aged over 85 years, increasing to 25.52 per 100,000 compared with 23.78 in the previous week. A decrease occurred in those aged 75 to 84 years with a mixed picture in the remaining age groups.


In week 36 (ending 8 September 2024), the overall weekly ICU or HDU admission rate for COVID-19 remained low and decreased to 0.07 per 100,000, compared with 0.11 per 100,000 in the previous week. Note that with very low rates in critical care, small random fluctuations may occur. Note that ICU or HDU admission rates may represent a lag from admission to hospital to an ICU or HDU ward. The ICU or HDU admission rate for COVID-19 by UKHSA centre or by age group is currently fluctuating at low levels due to low underlying numbers.



**Figure 3. Weekly overall COVID-19 hospital admission rates per 100,000 trust catchment population, reported through SARI Watch mandatory surveillance, England**



**Figure 4. Weekly overall COVID-19 ICU or HDU admission rates per 100,000 trust catchment population, reported through SARI Watch mandatory surveillance, England**



## ECMO, SARI Watch

There were 2 new corporeal membrane oxygenation (ECMO) admissions in adults (1 due to Adenovirus and 1 due to an Acute respiratory infection [ARI] without an identified pathogen) reported in week 36 from the 7 Severe Respiratory Failure (SRF) centres in the UK.

Please note that the other group includes other viral, bacterial or fungal ARI, suspected ARI, non-infection (such as asthma, primary cardiac and trauma) and sepsis of non-respiratory origin.

SARI Watch data is provisional and subject to retrospective updates.

## International update

### Global COVID-19 update

For further information on the global COVID-19 situation please see the [World Health Organization \(WHO\) COVID-19 situation reports](#).

### Global influenza update

For further information on the global influenza situation please see the [World Health Organization \(WHO\) Influenza update](#).

### Influenza in Europe

For further information on influenza in Europe please see the [European Respiratory Virus Surveillance Summary weekly update](#)

### Influenza in North and South America

For further information on influenza in the American continent please see the [Pan American Health Organisation influenza surveillance report](#). For further information on influenza in the United States of America please see the [Centre for Disease Control weekly influenza surveillance report](#). For further information on influenza in Canada please see the [Public Health Agency weekly influenza report](#).

### Influenza in Australia

For further information on influenza in Australia, please see the [Australian Influenza Surveillance Report and Activity Updates](#).

## Other respiratory viruses

### Avian influenza and other zoonotic influenza

For further information, please see the [latest WHO update](#) and the [latest UKHSA avian influenza technical risk assessment updated 25 July 2024](#).

### Middle East respiratory syndrome coronavirus (MERS-CoV)

For further information please see the [WHO disease outbreak news reports](#) and the [WHO monthly updates](#).

[Further information on management and guidance of possible cases](#) is available online. The latest highlights that risk of widespread transmission of MERS-CoV remains very low.

## Additional surveillance sources

### COVID-19 deaths

For further information on COVID-19 related deaths in England please see the [COVID-19 dashboard for death](#).

### All-cause mortality assessment (England)

For further information on all-cause mortality in England please see the [Excess mortality within England: post-pandemic method report](#), which uses Office for National Statistics (ONS) death registration data, [the all-cause mortality surveillance report](#), which uses the European mortality monitoring (EuroMOMO) model to identify weeks with higher than expected mortality and the [ONS all-cause excess mortality report](#).

### Flu Detector

For further information on syndromic surveillance please see the [daily influenza-like illness rates](#).

### Syndromic surveillance

For further information on syndromic surveillance please see the [syndromic surveillance: weekly summaries](#).

## Related links

[Previous national COVID-19 reports](#)

[Previous weekly influenza reports](#)

[Annual influenza reports](#)

[COVID-19 vaccine surveillance reports](#)

[Previous COVID-19 vaccine surveillance reports](#)

[Public Health England \(PHE\) monitoring of the effectiveness of COVID-19 vaccination](#)

[Investigation of SARS-CoV-2 variants of concern: technical briefings](#)

[Sources of surveillance data for influenza, COVID-19 and other respiratory viruses](#)

[RCGP virology dashboard](#)

UKHSA has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002.

Regulation 3 makes provision for the processing of patient information for the recognition, control and prevention of communicable disease and other risks to public health.

# About the UK Health Security Agency

UKHSA is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation health secure.

UKHSA is an executive agency, sponsored by the [Department of Health and Social Care](#).

© Crown copyright 2024

Prepared by: Immunisation and Vaccine Preventable Diseases Division  
For queries relating to this document, please contact: [respdsr.enquiries@ukhsa.gov.uk](mailto:respdsr.enquiries@ukhsa.gov.uk)

Published: 12 September 2024  
Publication reference: GOV-17259

**OGL**

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit [OGL](#). Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.



UKHSA supports the  
Sustainable Development Goals

**SUSTAINABLE  
DEVELOPMENT GOALS**